Hyderabad Feb 24 PTI COVID-19 vaccine Covaxin maker Bharat Biotech International Limited is in the process of bringing out a vaccine against tuberculosis and soon the firm will sign a MoU with another firm for technology Our honourable Prime Minister Narendra Modi has got an agenda of 2025 for the eradication of tuberculosis I think we are in that direction But we dont have the technology so we are partnering with somebody else On that matter we should be announcing soon Krishna Ella Chairman and Managing Director Bharat Biotech in panel discussion as part of BioAsia 2022 said Without providing details on the name of the firm with which BBIL will be inking MoU Ella said the TB vaccine is currently undergoing phase 3 clinical trials He said the immunology of the nasal vaccine being developed by the company against COVID-19 has been established Bharat Biotech had last month said BBV154 Nasal vaccine received approval for phase 3 clinical trials which will evaluate the jab for both the two-dose primary schedule and booster dose schedule PTI GDK GDK SS SS

Hyderabad Jan 28 PTI Bharat Biotech has received approval from the Drug Controller General of India to conduct phase-3 trials for its COVID-19 intra-nasal vaccine BBV154 sources in the company said on Friday The trials would evaluate the nasal vaccine for both the two-dose primary schedule and also to use as booster dose schedule they said BBV154 nasal covid vaccine has received approval for phase-3 clinical trials The trials will evaluate BBV154 nasal vaccine for both the two-dose primary schedule and booster dose schedule the sources said An intra-nasal vaccine would not only be simple to administer but also reduce the use of needles and syringes among others It would also impact the overall cost of a vaccination drive chairman of Bharat Biotech Krishna Ella had said PTI GDK NVG NVG

Hyderabad Dec 28 PTI State governments should ensure that every school or college has a library and a playground which would help develop students Chief Justice of India NV Ramana said here on Tuesday Delivering the valedictory address at the Hyderabad Book Fair Justice Ramana said book-reading is a good habit as it would leave an imprint in minds while playing sports would increase sporting spirit among children I dont think there are libraries in schools and colleges any more For any school or college to be set up library is a must This rule nobody is following Same is the case with playground This is a serious issue Governments should involve and solve this issue he said State governments should restore libraries in villages and provide grants for them he added He said literature and writers played key role in several struggles cross the world including the Indian freedom-fight Many Indian freedom fighters used to read a lot and write when they were languishing in prisons Justice Ramana said he read Maxim Gorkys novel Mother several times and it influenced him a lot He further said in this digital age except movie reviews one cannot find any good review on books PTI GDK NVG NVG

Hyderabad Dec 20 PTI Bharat Biotech has sought the Drug Controller General of Indias approval to conduct phase-3 trials of its COVID-19 intranasal vaccine BBV154 to use as booster dose sources said on Monday The application has been filed and the company is awaiting approval from the drug regulator The intranasal vaccine will be administered to those who have already taken their two-dose vaccine the sources told PTI An intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission Already conducted phase-2 with Bharat Biotechs Covaxin and with BBV154 Bharat Biotechs nasal vaccine Using a combination of one intra-muscular and the other nasal is an innovative approach of heterologus sources added Meanwhile the Central Drugs Standard Control Organisation approved the extension of Bharat Biotechs COVID-19 vaccine Covaxins shelf life up to 12 months from the date of manufacture the vaccine-maker said in a press release This approval of shelf life extension is based on the availability of additional stability data which was submitted to CDSCO With the shelf life extension hospitals can now utilise the stock which was nearing expiry and avoid vaccine wastage it said Covaxin is approved for use under the 28-day multi-dose vial policy from Drugs Controller General of India and the WHO Emergency Use Listing WHO EUL Covaxin Open Vial is stable at 2 to 8 degrees Celsius for 28 days and not required to be discarded immediately in a day or at the end of immunisation session Bharat Biotech said it believes in doing a bit to care for the environment The multi-dose vial policy saves money for procurement agencies by reducing the cold chain logistics and management thereby reducing the carbon footprint costs related to open vial wastage cold chain distribution cold chain storage and biomedical waste disposal among others Most importantly we believe in being environmentally friendly by reducing the quantum of packing materials and single use plastics that are utilised in vaccines-manufacturing storage distribution and disposal the company said PTI GDK NVG NVG

Hyderabad Nov 19 PTI The power of people is always greater than the people in power Telangana Minister and TRS Working President KT Rama Rao said on Friday reacting to Prime Minister Narendra Modis statement on repealing the three farm laws The power of people is always greater than the people in power Proved once again by the Indian farmers who got what they demanded by their relentless agitation Jai Kisan Jai Jawan KTR tweeted Chief Minister K Chandrashelhar Rao on Thursday holding protests asserted that TRS would fight till the end over the NDA governments anti-people policies and anti-farm laws Repealing the farm laws is a victory of agitating farmers of the country Telangana PCC president Revanth Reddy said in a statement complementing the peasant community for their incessant stir against the new legislations This is a historic victory in the history of farmers struggle Even dictators would succumb to the anger of farmers who are the backbone of the country Reddy said All the tactics being applied to suppress the farmers agitation became futile and had the Centre realised the seriousness of the situation in time so many lives lost in the agitation would have been saved he added The farmers stir inspired other agitations on public causes the congress leader said Various farmers unions have been protesting at the borders of the national capital since last year to demand repeal of three farm laws In Telangana the state Congress unit is currently undertaking various agitational programmes against the Centre and the TRS government on procurement of paddy from farmers PTI GDK SS SS

Hyderabad Sep 17 PTI Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine Covaxin to the World health organisation for Emergency Use Listing EUL and is awaiting feedback from the global health watchdog The WHO is currently reviewing the data submitted by the vaccine maker and the date for a decision on the jab is yet to be confirmed according to the update available on WHO website COVAXIN clinical trial data was fully compiled available in June 2021 All Data submitted for Emergency Use Listing EUL Application to World Health Organization in early July We have responded to any clarifications sought by WHO and are awaiting further feedback Bharat Biotech tweeted As a responsible manufacturer with past approvals for its other vaccines the company said it would not find it appropriate to speculate or comment on approval process and its timelines it further said We are continuing to work diligently on obtaining WHO EUL at the earliest the vaccine maker added in a series of tweets In an update on its website the WHO said it began rolling data of the vaccine on July 6 Rolling data allows the WHO to start its review right away as information continues to come in to accelerate the overall review process Suchitra Ella joint managing director of Bharat Biotech recently had earlier said the EUL process is a step closer to the final decision on Covaxins global acceptance PTI GDK SS SS